CSII is related to more stable glycemia in adults with type 1 diabetes.
Continuous subcutaneous insulin infusion
Glycemic variability
Multiple daily injections
Type 1 diabetes
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
05
08
2021
accepted:
13
10
2021
pubmed:
26
10
2021
medline:
24
3
2022
entrez:
25
10
2021
Statut:
ppublish
Résumé
The purpose of the present study was to compare the basic glycemic control parameters-HbA1c, CV%, and hypoglycemia, as well as quality of life and depression score in patients with type 1 diabetes using continuous subcutaneous insulin infusion (CSII) versus multiple daily injections (MDI). 324 adult patients with type 1 diabetes-146 using CSII and 178 on MDI, were enrolled in this cross-sectional study. HbA1c was assessed in whole blood by immuno-turbidimetric NGSP certified method. CV% was derived from CGM or was calculated from a 9-point capillary blood glucose profile. Hypoglycemia frequency, severity, and awareness were assessed using Clarke's hypoglycemia questionnaire. Quality of life (QOL) was assessed using a questionnaire by the Psychiatric Research Unit and the CES-D scale. CSII group compared to MDI group showed significantly lower HbA1c-7.3% (6.6-8.0%) vs 8.2% (7.2-9.6%) (p < 0.0001), lower CV 27.2% (±9.8) vs 34.7% (±11.3) (p < 0.0001), fewer hypoglycemia episodes (p < 0.0001). There was no significant difference in the frequency of severe hypoglycemia, hypoglycemia awareness, QOL, and depression scores between the two groups. CSII in type 1 diabetes is related to better and more stable glycemic control compared to MDI.
Identifiants
pubmed: 34694598
doi: 10.1007/s12020-021-02913-9
pii: 10.1007/s12020-021-02913-9
doi:
Substances chimiques
Blood Glucose
0
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
Insulin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
776-780Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
R.P. Radermecker, A.J. Scheen,, Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness. Diabetes Metab. Res. Rev. 20(3), 178–188 (2004). https://doi.org/10.1002/dmrr.447.
doi: 10.1002/dmrr.447.
pubmed: 15133748
National Institute for Health and Care Excellence. Diabetes in pregnancy: management from preconception to the postnatal period. https://www.nice.org.uk/guidance/ng3/chapter/Recommendations (2015). Accessed 01 July 2021.
U. Mantaj, P. Gutaj, K. Ozegowska, A. Zawiejska, K. Wroblewska-Seniuk, D. Olejniczak, E. Wender-Ozegowska, Continuous subcutaneous insulin infusion reduces neonatal risk in pregnant women with type 1 diabetes mellitus. Ginekol Pol. 90(3), 154–160 (2019). https://doi.org/10.5603/GP.2019.0028.
doi: 10.5603/GP.2019.0028.
pubmed: 30950005
M.A. Martínez-Brocca, Benefits of continuous subcutaneous insulin infusion in type 1 diabetes. Is there any doubt? Endocrinol Nutr. 63(3), 103–105 (2016). https://doi.org/10.1016/j.endonu.2015.11.006.
doi: 10.1016/j.endonu.2015.11.006.
pubmed: 26775015
J.C. Pickup, A.J. Sutton, Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet. Med. 25(7), 765–774 (2008). https://doi.org/10.1111/j.1464-5491.2008.02486.x.
doi: 10.1111/j.1464-5491.2008.02486.x.
pubmed: 18644063
J. Pickup, M. Mattock, S. Kerry, Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 324(7339), 705 (2002). https://doi.org/10.1136/bmj.324.7339.705.
doi: 10.1136/bmj.324.7339.705.
pubmed: 11909787
pmcid: 99054
J.C. Summers, E.M. Briganti, Z.A. Fitzgerald, L.N.J. Lambers, N.D. Cohen, Long-Term Effectiveness of Continuous Subcutaneous Insulin Infusion in the Prevention of Hypoglycemia in Adults with Type 1 Diabetes. Diabetes Technol. Ther. 21(8), 423–429 (2019). https://doi.org/10.1089/dia.2019.0108.
doi: 10.1089/dia.2019.0108.
pubmed: 31180239
P. Beato-Víbora, E. Yeoh, H. Rogers, D. Hopkins, S.A. Amiel, P. Choudhary, Sustained benefit of continuous subcutaneous insulin infusion on glycaemic control and hypoglycaemia in adults with Type 1 diabetes. Diabet. Med. 32(11), 1453–1459 (2015). https://doi.org/10.1111/dme.12869.
doi: 10.1111/dme.12869.
pubmed: 26213236
S.M. Blackman, D. Raghinaru, S. Adi et al. Insulin pump use in young children in the T1D Exchange clinic registry is associated with lower hemoglobin A1c levels than injection therapy. Pediatr. Diabetes 15(8), 564–572 (2014). https://doi.org/10.1111/pedi.12121.
doi: 10.1111/pedi.12121.
pubmed: 24494980
J. Olsovský, M. Beránek, The influence of long-term therapy with the insulin pump (CSII) in patients with type 1 diabetes mellitus on metabolic compensation and on the incidence of hypoglycaemia. Comparison with intensified conventional insulin therapy (MDI). Vnitr. Lek. 53(6), 637–645 (2007). PMID: 17702123.
pubmed: 17702123
M.I. Maiorino, G. Bellastella, O. Casciano et al. The Effects of Subcutaneous Insulin Infusion Versus Multiple Insulin Injections on Glucose Variability in Young Adults with Type 1 Diabetes: The 2-Year Follow-Up of the Observational METRO Study. Diabetes Technol. Ther. 20(2), 117–126 (2018). https://doi.org/10.1089/dia.2017.0334.
doi: 10.1089/dia.2017.0334.
pubmed: 29303370
B. Simon, V. Treat, C. Marco et al. A comparison of glycaemic variability in CSII vs. MDI treated type 1 diabetic patients using CGMS. Int. J. Clin. Pract. 62(12), 1858–1863 (2008). https://doi.org/10.1111/j.1742-1241.2008.01932.x.
doi: 10.1111/j.1742-1241.2008.01932.x.
pubmed: 19166434
R. Linkeschova, M. Raoul, U. Bott, M. Berger, M. Spraul, Less severe hypoglycaemia, better metabolic control, and improved quality of life in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diabet. Med. 19(9), 746–751 (2002). https://doi.org/10.1046/j.1464-5491.2002.00713.x.
doi: 10.1046/j.1464-5491.2002.00713.x.
pubmed: 12207811
M. Lozano-Serrano, J.A. García-Seco, F. García-Seco et al. Satisfaction and quality of life evaluation in patients with type 1 diabetes mellitus treated using continuous subcutaneous insulin infusion compared with multiple daily injections. Enferm. Clin. 23(3), 96–102 (2013). https://doi.org/10.1016/j.enfcli.2013.02.004.
doi: 10.1016/j.enfcli.2013.02.004.
pubmed: 23755944
American Diabetes Association Workgroup on Hypoglycemia, Defining and Reporting Hypoglycemia in Diabetes. Diabetes Care 28(5), 1245–1249 (2005). https://doi.org/10.2337/diacare.28.5.1245 .
doi: 10.2337/diacare.28.5.1245
NICE. Type 1 diabetes in adults: diagnosis and management. https://www.nice.org.uk/guidance/ng17/chapter/Recommendations#hypoglycaemia-awareness-and-management (2015). Accessed 01 July 2021.
L.S. Radloff, The CES-D scale: A self report depression scale for research in the general population. Appl. Psychol. Measurements. 1, 385–401. (1977) https://doi.org/10.1177/014662167700100306 .
C.W. Topp, S.D. Østergaard, S. Søndergaard, P. Bech, The WHO-5 Well-Being Index: a systematic review of the literature. Psychother Psychosom 84(3), 167–176 (2015). https://doi.org/10.1159/000376585.
doi: 10.1159/000376585.
pubmed: 25831962
Danne T., Nimri R., Battelino T., et al. International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care 40(12), 1631–1640. https://doi.org/10.2337/dc17-1600 .
NICE. Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus. https://www.nice.org.uk/guidance/ta151/chapter/1-Guidance (2008). Accessed 1 July 2021.
I. Martín-Timón, F.J. Del Cañizo-Gómez, Mechanisms of hypoglycemia unawareness and implications in diabetic patients. World J Diabetes 6(7), 912–926 (2015). https://doi.org/10.4239/wjd.v6.i7.912.
doi: 10.4239/wjd.v6.i7.912.
pubmed: 26185599
pmcid: 4499525
M. Visser, S. Charleer, S. Fieuws, et al. Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial. Lancet. 2021. https://doi.org/10.1016/S0140-6736(21)00789-3 .